PRODH2

Across TCGA pan-cancer cohorts, PRODH2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRODH2 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PRODH2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRODH2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

BRCA, SKCM, and LIHC are the cancer types where PRODH2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.418	0.903	.007	12	view →
SKCM	DFS	Median	II,III,IV	0.753	0.211	.010	11	view →
LIHC	OS	Median	All	0.164	0.704	.025	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.446	.047	2	view →
SCLC	OS	Median	All	1.000	0.249	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRODH2–BRCA (DFS)

Open the BRCA breakdown →